A carregar...
Intravenous immunoglobulins for the treatment of mild to moderate Alzheimer’s disease: a phase II, randomised, double-blind, placebo-controlled dose-finding trial
BACKGROUND: Three small trials have suggested effects of intravenous immunoglobulins (IVIG) on biomarkers and symptoms of mild-to-moderate Alzheimer’s disease (AD). We explored the safety, the effective dose, and the infusion interval for Octagam(®)10% in this patients’ group. METHODS: The study was...
Na minha lista:
| Publicado no: | Lancet Neurol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4986921/ https://ncbi.nlm.nih.gov/pubmed/23375965 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1474-4422(13)70014-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|